Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone

Diagn Microbiol Infect Dis. 2008 Mar;60(3):319-22. doi: 10.1016/j.diagmicrobio.2007.09.017. Epub 2007 Nov 9.

Abstract

We report the use of tigecycline, firstly with colistin and finally alone, in a patient with a persistent breakthrough bacteremia due to a Klebsiella pneumoniae isolate harboring a metallo-beta-lactamase (VIM-1) and an extended-spectrum beta-lactamase (SHV-12). Time-kill studies demonstrated that the combination of both compounds was synergistic along the first 12 h, suppressing the regrowth observed after 3 to 6 h when colistin was tested alone.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy*
  • Colistin / therapeutic use
  • Drug Synergism
  • Drug Therapy, Combination
  • Humans
  • Klebsiella Infections / drug therapy*
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / enzymology
  • Male
  • Microbial Sensitivity Tests
  • Microbial Viability
  • Minocycline / analogs & derivatives*
  • Minocycline / therapeutic use
  • Tigecycline
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • Tigecycline
  • beta-Lactamases
  • Minocycline
  • Colistin